Article Text

Download PDFPDF
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
  1. Aaron Z Reyes1,
  2. Kelly A Hu1,
  3. Jacob Teperman1,
  4. Theresa L Wampler Muskardin2,3,
  5. Jean-Claude Tardif4,
  6. Binita Shah5,6,
  7. Michael H Pillinger3,7
  1. 1 Internal Medicine, New York University Grossman School of Medicine, New York, New York, USA
  2. 2 Colton Center for Autoimmunity, Department of Medicine and Pathology, New York University School of Medicine, New York, New York, USA
  3. 3 Rheumatology/Medicine, New York University Grossman School of Medicine, New York, New York, USA
  4. 4 Montreal Heart Institute, Montreal, Québec, Canada
  5. 5 Cardiology/Medicine, New York University Grossman School of Medicine, New York, New York, USA
  6. 6 Cardiology/Medicine, VA New York Harbor Healthcare System, New York, New York, USA
  7. 7 Rheumatology/Medicine, VA New York Harbor Healthcare System, New York, New York, USA
  1. Correspondence to Dr Michael H Pillinger, Rheumatology, New York University School of Medicine, New York, NY 10016, USA; Michael.Pillinger{at}nyulangone.org

Abstract

The search for effective COVID-19 management strategies continues to evolve. Current understanding of SARS-CoV-2 mechanisms suggests a central role for exaggerated activation of the innate immune system as an important contributor to COVID-19 adverse outcomes. The actions of colchicine, one of the oldest anti-inflammatory therapeutics, target multiple mechanisms associated with COVID-19 excessive inflammation. While many COVID-19 trials have sought to manipulate SARS-CoV-2 or dampen the inflammatory response once patients are hospitalised, few examine therapeutics to prevent the need for hospitalisation. Colchicine is easily administered, generally well tolerated and inexpensive, and holds particular promise to reduce the risk of hospitalisation and mortality due to COVID-19 in the outpatient setting. Successful outpatient treatment of COVID-19 could greatly reduce morbidity, mortality and the demand for rare or expensive care resources (front-line healthcare workers, hospital beds, ventilators, biological therapies), to the benefit of both resource-replete and resource-poor regions.

  • cytokines
  • inflammation
  • chemokines
  • immune system diseases
  • therapeutics

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • AZR, KAH and JT are joint first authors.

  • BS and MHP are joint senior authors.

  • Handling editor Josef S Smolen

  • Twitter @azrys

  • Contributors All authors contributed to conception or design of the work; and drafting the work or revising it critically for important intellectual content; and final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests For the purposes of full disclosure, we note that BS receives support from the NIH/NHLBI (1R01HL146206, 3R01HL146206-02S1) and VA ORD (iK2CX001074) for her work on colchicine in cardiovascular disease and COVID-19. J-CT reports grants and personal fees from Amarin, grants and personal fees from AstraZeneca, grants, personal fees and other from DalCor, grants from Esperion, grants from Ionis, grants and personal fees from Pfizer, grants and personal fees from Sanofi, grants and personal fees from Servier, personal fees from HLS Therapeutics, outside the submitted work; In addition, J-CT has a patent on pharmacogenomics-guided CETP inhibition issued, and a patent on the use of colchicine after myocardial infarction pending. MHP holds investigator-initiated grants from Horizon Therapeutics (to study urate deposition in the spines of gout patients) and Hikma Pharmaceuticals (to study the possible benefit of colchicine in knee osteoarthritis) and has served as a consultant for Horizon and Sobi. MHP also receives salary support from a CTSA award (1UL1TR001445) to New York University from the National Centre for the Advancement of Translational Science, National Institutes of Health. TLWM is supported by an NYU‐HHC Clinical and Translational Science Institute KL2 grant and a Doris Duke Fund to Retain Clinical Scientists award. TLWM has served on an advisory board for Novartis and as a consultant to Regeneron, unrelated to this work

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.